Contact: Vicki Cohn, (914) 740-2156, firstname.lastname@example.org
New Method Yields Potent, Renewable Human Stem Cells with Promising Therapeutic Properties
New Rochelle, NY, March 24, 2014—The curative and therapeutic potential of mesenchymal stem cells (MSCs) offers much promise, as these multipotent cells are currently being tested in more than 300 clinical trials in a range of diseases. A new, easier, and more reliable way to make large quantities of highly potent MSCs could accelerate progress toward their use in regenerative medicine, as described in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website.
Robert Lanza, MD and colleagues from Advanced Cell Technology (Marlborough, MA) and the David Geffen School of Medicine, UCLA (Los Angeles, CA), developed an innovative method for deriving MSCs from human embryonic stem cells (hESCs) through the use of a developmental precursor called the hemangioblast. They describe the technique and evidence of therapeutic efficacy using the hESC-MSCs to treat mouse models of lupus erythematosus and uveitis in the article “Mesenchymal Stem Cell Population Derived from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties.”
“This new population of hESC-derived MSCs has a 30,000-fold greater proliferative capacity than bone marrow-derived MSCs,” says Dr. Lanza, Chief Scientific Officer, Advanced Cell Technology. “In addition to being easy to derive in very large numbers, they are more youthful and live much longer.” Dr. Lanza is Editor-in-Chief of BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers that provides a rapid-publication forum for a broad range of scientific topics.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year online with Open Access options and in print. Led by Editor-in-Chief Graham C. Parker, PhD, the Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. Complete tables of content and a sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.